Cofactor Genomics, a San Francisco, CA-based developer of a platform for RNA sequencing and expression analysis, raised $18M in financing.
The round was led by Menlo Ventures with participation from existing investor Data Collective (DCVC) and new investor Ascension Ventures, and participation from existing and new investors iSelect, Y Combinator, Wilson Sonsini Goodrich & Rosati, and Stanford. In conjunction with the funding, Mark Siegel (Menlo Ventures), Matt Ocko (DCVC), and John Kuelper (Ascension Ventures) joined Cofactor’s board of directors.
Led by Dr. Jarret Glasscock, CEO, Cofactor Genomics uses RNA to enable researchers and clinicians to understand, diagnose, and predict drug response for the 95% of disease that can’t be assessed by DNA alone. The company has built a proprietary platform capable of performing complex RNA fingerprint analysis on clinical-grade human samples for the world’s largest pharma and biotech companies, and is in the process of commercializing a suite of clinical diagnostic assays targeting oncologic, immunologic, and neurodegenerative diseases.
Cofactor’s products include Pinnacle, which examines nearly 600 RNA biomarkers known to be associated with response to targeted therapeutics, and Paragon, an RNA-based immunophenotyping assay with broad applications to the field of Immuno-Oncology and beyond.